A preclinical "magic bullet" against fibrolamellar hepatocellular carcinoma?

Mol Ther. 2024 Jan 3;32(1):9-10. doi: 10.1016/j.ymthe.2023.12.002. Epub 2023 Dec 16.

Authors

Coline Ducrot¹, Max Piffoux²

Affiliations

¹ Pediatric Orthopedic Surgery Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France; Team Cell Death and Pediatric Cancer, Cancer Initiation and Tumor Cell Identity Department, INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.
² Medical Oncology, Hospices Civils de Lyon, CITOHL, Lyon, France; Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: max.piffoux@chu-lyon.fr.

PMID: 38104561
PMCID: PMC10787162 (available on 2025-01-03)
DOI: 10.1016/j.ymthe.2023.12.002

No abstract available

MeSH terms

Carcinoma, Hepatocellular* / genetics
Carcinoma, Hepatocellular* / pathology
Humans
Liver Neoplasms* / genetics
Liver Neoplasms* / pathology

Supplementary concepts

Fibrolamellar hepatocellular carcinoma